This ADC product is comprised of an anti-CD22 monoclonal antibody conjugated via a DIBO linker to a doxorubicin. The doxorubicin is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten